Indivior Unable to Participate in Morgan Stanley Healthcare Conference Due to Adverse Weather

SLOUGH, England, Sept. 12 -- Indivior, a pharmaceutical company, issued the following news release:

Indivior PLC (LON: INDV) today announced that due to adverse weather expected from Hurricane Florence, the recently declared state of emergency in Virginia and its likely impact on East Coast travel, the Company is unable to participate in Morgan Stanley's 16th Annual Global Healthcare Conference.

Shaun Thaxter, CEO, was scheduled to address conference attendees on Thursday, September 13th at 11:10 a.m. Indivior has published a SUBLOCADE(TM) (buprenorphine extended-release) Injection Update on its website at www.indivior.com under "Webcasts / Audiocasts / Presentations."

Shaun Thaxter, CEO of Indivior, Comment: "Experience and satisfaction with SUBLOCADE continues to be positive based on anecdotal reports from both patients and physicians. While early challenges remain, the metrics we have today published demonstrate that we are continuing to make steady progress in reducing the time taken for the prescription journey, improved payor coverage, as well as demonstrating increased trial and adoption by healthcare professionals. We believe HCP adoption will increase progressively as we sustain the progress we are making to alleviate frustration with the medical benefits approval process and improve the timing of the prescription journey for the patient. We continue to expect full year 2018 net revenues to be in the range of $25 million to $50 million, with sales heavily weighted to the fourth quarter, and we remain confident in achieving our annual peak net revenue goal of $1 billion-plus."

Teva Cassipsa(R)

Indivior also announced that Teva has agreed that market entry of its recently FDA approved buprenorphine and naloxone (16mg/4mg) sublingual film will be tied to the outcome of the U.S. Court of Appeals for the Federal Circuit (CAFC) decision on the preliminary injunction that was granted by the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (DRL). This agreement will prevent Teva from selling, offering to sell, or import its generic buprenorphine/naloxone sublingual film product until the earlier of a CAFC decision lifting the preliminary injunction against DRL, and the outcome of filed litigation against DRL related to U.S. patent Nos. 9,931,305, 9,855,221, and 9,687,454.

The CAFC has granted DRL an expedited appeal on the preliminary injunction. Arguments are scheduled to be heard on October 4th, with a decision expected in early November.

Indivior Investor Day

Indivior is confirming that it will hold an Investor Day on Wednesday, December 5th, 2018 in New York City. Presentations will be given by Chief Executive Officer Shaun Thaxter and members of the Indivior management team. The event will begin at approximately 9:00 a.m. Eastern Time. A live video / audio webcast of the event, as well as the presentation slides, will be available to the public on the day of the event on the Company's website at www.indivior.com. Additional event details to follow. The Indivior team will be available to speak with investors one-on-one on September 13th and 14th. Please contact Jason Thompson, Investor Relations, at 804-379-1033 to arrange a time.